Samarium-153 (Quadramet)
Also known as Samarium Sm 153 Lexidronam Injection.
General information
Class/mechanism: Radioactive pharmaceutical agent (Samarium-153) that concentrates in areas of bone turnover associated with hydroxyapatite and releases beta and gamma radiation. Samarium-153 accumulates in osteoblastic lesions about 5 times as much as normal bone. Samarium-153's half-life is 46.3 hours.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Patient drug information
- Patient counseling information about getting started with Quadramet[3]
- Quadramet manufacturer's patient handout about cancer-related bone pain[4]
- Samarium-153 (Quadramet) patient drug information (UpToDate)[5]
References
- ↑ 1.0 1.1 Samarium-153 (Quadramet) package insert
- ↑ Samarium-153 (Quadramet) package insert (locally hosted backup)
- ↑ Patient counseling information about getting started with Quadramet
- ↑ Quadramet manufacturer's patient handout about cancer-related bone pain
- ↑ Samarium-153 (Quadramet) patient drug information (UpToDate)